In order to improve the lives of those living with CKD, we know that we must think boldly and move bold thinking into action. That is why we work with partners across the globe to pioneer and grow new areas of research and development.
The HIF Pathway
The hypoxia-inducible factor (HIF) pathway is the master regulator of our body’s adaptive response to oxygen availability. This fundamental oxygen-sensing pathway is responsible for the transcription of a broad range of genes involved in maintaining our biological homeostasis.1 Scientific advancement in understanding how the HIF pathway regulates physiological processes culminated in 2019 with the award of the Nobel Prize in Physiology or Medicine. The discovery of HIF has laid the foundation to understanding the central role of oxygen sensing in many diseases, including anemia due to CKD.2,3
Vadadustat Clinical Program
Explore our clinical development program evaluating vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of anemia due to CKD in dialysis and non-dialysis patients.View
Vadadustat is an investigational new drug and has not been approved by the FDA.
1. Ke Q, et al. Mol Pharmacol. 2006;70(5):1469-1480.
2. Liao C, et al. Am J Pathol. 2020;190(8):1584-1595.
3. Liu J, et al. Int J Mol Sci. 2017;18(5):950.